631901-41-2Relevant academic research and scientific papers
Synthesis and evaluation of 4/5-hydroxy-2,3-diaryl(substituted)-cyclopent- 2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anticancer agents
Gurjar, Mukund K.,Wakharkar, Radhika D.,Singh, Anu T.,Jaggi, Manu,Borate, Hanumant B.,Shinde, Popat D.,Verma, Ritu,Rajendran, Praveen,Dutt, Sarjana,Singh, Gurvinder,Sanna, Vinod K.,Singh, Manoj K.,Srivastava, Sanjay K.,Mahajan, Vishal A.,Jadhav, Vinod H.,Dutta, Kakali,Krishnan, Karthik,Chaudhary, Anika,Agarwal, Shiv K.,Mukherjee, Rama,Burman, Anand C.
, p. 1744 - 1753 (2008/02/02)
A new series of 2,3-diaryl-4/5-hydroxy-cyclopent-2-en-1-one analogues replacing the cis double bond of combretastatin A-4 (CA-4) by 4/5-hydroxy cyclopentenone moieties was designed and synthesized. The analogues displayed potent cytotoxic activity (ICsub
CYCLOPENTENONE DERIVATIVES FOR CANCER THERAPY
-
Page 25, (2010/02/07)
The invention relates to the use of derivatives of cyclopentenone for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention relates more specifically to the u
Cyclopentenone derivatives for cancer therapy
-
Page 12-13, (2010/02/05)
The invention relates to the use of derivatives of cyclopentenone for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention relates more specifically to the u
